NXX-066 in patients with Alzheimer's disease: A bridging study

Life Sciences

Volumn 64, Issue 14, 1999, Pages 1215-1221

  Sramek, John J ^a   Hourani, Jameel ^a   Jhee, Stanford S ^a   Cutler, Neal R ^a  

^a CALIFORNIA CLINICAL TRIALS   (United States)

Author keywords

Alzheimer's disease; Bridging study; NXX 066

Indexed keywords

CHOLINERGIC RECEPTOR BLOCKING AGENT; NXX 066; PHYSOSTIGMINE DERIVATIVE; PLACEBO; UNCLASSIFIED DRUG;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; ASTHENIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG TOLERANCE; ELECTROCARDIOGRAM; FEMALE; HEADACHE; HUMAN; HUMAN EXPERIMENT; MALE; MEMORY; NAUSEA; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; TREATMENT PLANNING; VERTIGO; VOMITING;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INDOLES; ISOQUINOLINES; MALE; MIDDLE AGED;

ANIMALIA;

EID: 0033605046     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0024-3205(99)00053-3     Document Type: Article

References (17)

1. M. Weinstock. Neurodegeneration. 4 349-56 (1995).
2. G. Pacheco, R. Palacios-Esquivel, and D.E. Moss. J. Pharmacol. Exp. Ther. 274 767-70 (1995).
3. H. Sugimoto, Y. Iimura, Y. Yamanishi, and K. Yamatsu. J. Med. Chem. 38 4821-9 (1995).
4. M. Brufani, L. Filocamo, E. Imbriani, S. Lappa, and L. Mannina. Farmaco 40 743-5 (1994).
5. N. Canal and B.P. Imbimbo. Clin. Pharmacol. Ther. 60 218-28 (1996).
6. S. Asthana, N.H. Greig, L. Hegedus, H.H. Holloway, K.C. Raffaele, M.B. Schapiro, and T.T. Soncrant. Clin. Pharmacol. Ther. 58 299-309 (1995).
7. Data on file. Astra, U.S.A.
8. N.R. Cutler and J.J. Sramek. Eur. J. Clin. Pharmacol. 48 421-428 (1995).
9. N.R. Cutler and J.J. Sramek. Alzheimer Dis. Assoc. Disord. 9 139-145 (1995).
10. N.R. Cutler and J.J. Sramek. Neurodegeneration 5 511-514 (1996).
11. N.R. Cutler, J.J. Sramek, D.J. Greenblatt, P. Chaikin, N. Ford, L.J. Lesko, B. Davis, and R. Williams. J. Clin. Pharmacol. 37 767-783 (1997).
12. K.B. Augustinsson, H. Eriksson, and Y. Faijersson. Clin. Chem. Acta 89 239-252 (1978).
13. J.J. Sramek, D.J. Hurley, T.S. Wardle, J.H. Satterwhite, J. Hourani, F. Dies, and N.R. Cutler. J. Clin. Pharmacol. 35 800-806 (1995).
14. J.J. Sramek, G.A. Block, S.A. Reines, S.F. Sawin, A. Barchowsky, and N.R. Cutler. Life Sci. 56 319-326 (1995).
15. N.R. Cutler, J.J. Sramek, R.D. Seifert, and S.F. Sawin. Therapeutics 64 559-562 (1993).
16. N.R. Cutler and J.J. Sramek. Research Advances in Alzheimer's Disease and Related Disorders, K. Iqbal, J.A. Mortimer, B. Winblad, and H.M. Wisniewski (Eds.) John Wiley & Sons, Ltd, Chichester (1995).
17. N.R. Cutler and J.J. Sramek. Alzheimer Disease: From Molecular Biology to Therapy, R. Becker and E. Giacobini (Eds.) Birkhäuser, Boston (1996).